The largest clinical trial of peanut allergy desensitization was completed by DBV Technologies. The results of their Phase IIB trial for their Viaskin Peanut showed it is effective at reducing the effects of peanut allergies, the company says.

The study involved 221 peanut allergic subjects in 22 locations in North American and Europe. The double-blind placebo-controlled food challenges were used to prove efficacy for Viaskin.

In a release, DBV announced that the highest explored dose of Viaskin Peanut showed statistical significance in desensitizing a higher proportion of patients when compared to a placebo. In short, according to DBV, their trails showed that patients who were put on the Viaskin Peanut program were more likely to be less sensitive to peanut reactions than were those who were not.

“This is a crucial step toward finding a safe treatment for this unmet medical need and we plan to enter into a phase III program informed by the results of the VIPES trial in all patient populations in approximately 12 to 18 months,” said Dr. Pierre-Henri Benhamou, Chairman and Chief Executive Officer of DBV Technologies.

The DBV numbers show that 53.6 percent of children responded to treatment (vs. 19.4 percent in placebo). Adolescents showed a response rate of 38.9 percent, though 22.2 percent also responded to placebo, making this statistically significant. Adults were found inconclusive as their sample size was too small to produce accurate results.

DBV has not announced when Phase III trials will begin.

Leave a Reply

Your email address will not be published. Required fields are marked

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}